Form 8-K - Current report:
SEC Accession No. 0001213900-25-059289
Filing Date
2025-06-30
Accepted
2025-06-30 09:01:28
Documents
17
Period of Report
2025-06-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0247451-8k_kyverna.htm   iXBRL 8-K 39815
2 EMPLOYMENT OFFER LETTER, DATED JUNE 5, 2025, BETWEEN KYVERNA THERAPEUTICS, INC. ea024745101ex10-1_kyverna.htm EX-10.1 112219
3 LETTER AGREEMENT, ENTERED INTO ON JUNE 28, 2025, BETWEEN KYVERNA THERAPEUTICS, I ea024745101ex10-2_kyverna.htm EX-10.2 54808
4 PRESS RELEASE, DATED JUNE 30, 2025 ea024745101ex99-1_kyverna.htm EX-99.1 15170
5 GRAPHIC ex10-1_001.jpg GRAPHIC 9766
6 GRAPHIC ex10-2_001.jpg GRAPHIC 7889
  Complete submission text file 0001213900-25-059289.txt   465500

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE kytx-20250630.xsd EX-101.SCH 3017
8 XBRL LABEL FILE kytx-20250630_lab.xml EX-101.LAB 34239
9 XBRL PRESENTATION FILE kytx-20250630_pre.xml EX-101.PRE 22360
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0247451-8k_kyverna_htm.xml XML 3689
Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Filer) CIK: 0001994702 (see all company filings)

EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41947 | Film No.: 251088906
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)